Brief: Tetra Bio-Pharma Receives EMA Orphan Drug Designation For A Novel Topical Therapeutic Containing Cbd
18/05/2022 13:00
Tetra Bio Pharma Inc TBP.TO :
* TETRA BIO-PHARMA RECEIVES EMA ORPHAN DRUG DESIGNATION FOR
A
NOVEL TOPICAL THERAPEUTIC CONTAINING CBD
* TETRA BIO PHARMA INC- DRUG IS READY FOR HUMAN CLINICAL
TRIALS
Source text for Eikon: ID:nCNWV4Xkpa
Further company coverage: TBP.TO
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding